Actively Recruiting
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Led by Accession Therapeutics Limited · Updated on 2026-03-25
72
Participants Needed
7
Research Sites
510 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.
CONDITIONS
Official Title
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Consenting male and female adults 18 years of age or older with select solid epithelial tumours expressing the αvβ6 integrin receptor
- Have received and failed or are intolerant to standard of care therapy (excluding neoadjuvant)
- Have a tumour lesion not previously treated with radiation and suitable for biopsy before and after treatment
- Have measurable disease according to RECIST Version 1.1
- Have an ECOG Performance Status of 0 or 1
- Have a life expectancy greater than three months
- Willing to follow hygiene measures to prevent virus spread and protect vulnerable people
- Have adequate organ function
- Comply with prior treatment washout and contraceptive requirements related to genetically modified organisms and cancer therapies
- May have received prior immune checkpoint antibody therapies alone or with other anti-cancer agents
You will not qualify if you...
- Have significant fibrotic disease, including autoimmune diseases like systemic lupus or rheumatoid arthritis, or pulmonary fibrosis
- Have a known history of intolerance to anti-PD-1 or anti-PD-L1 immunotherapy due to toxicity
- Have any other comorbid conditions listed in the detailed protocol exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
START Barcelona
Barcelona, Spain
Actively Recruiting
2
Start Fjd
Madrid, Spain
Actively Recruiting
3
Start Hm Ciocc
Madrid, Spain
Actively Recruiting
4
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
Actively Recruiting
5
Velindre Cancer Centre
Cardiff, Wales, United Kingdom
Actively Recruiting
6
, St James' University Hospital
Leeds, United Kingdom
Actively Recruiting
7
Churchill Hospital
Oxford, United Kingdom
Actively Recruiting
Research Team
H
Hardev Pandha, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here